About 40% of patients with myelodysplastic syndromes (MDSs) present with a normal karyotype, and they are facing different courses of disease. To advance the biological understanding and to find molecular prognostic markers, we performed a highresolution oligonucleotide array study of 107 MDS patients (French American British) with a normal karyotype and clinical follow-up through the Duesseldorf MDS registry. Recurrent hidden deletions overlapping with known cytogenetic aberrations or sites of known tumor-associated genes were identified in 4q24 (TET2, 2x), 5q31.2 (2x), 7q22.1 (3x) and 21q22.12 (RUNX1, 2x). One patient with a 7q22.1 deletion had an additional 5q31.2 deletion of the acute myeloid leukemia/MDS region, the smallest deletion identified so far and including the putative tumor suppressor (ts) genes, EGR1 and CTNNA1. One TET2 deletion was homozygous and one heterozygous, with a missense mutation in the remaining allele, further supporting its role as a ts gene. Besides these recurrent alterations, additional individual imbalances were found in 34 cases; in total, 42/107 (39%) cases had genomic imbalances. These patients had an inferior survival as compared with the rest of the patients (P ¼ 0.002). This study emphasizes the heterogeneity of MDS, but points to interesting genes that may have diagnostic and prognostic impact.
Introduction
The myelodysplastic syndromes (MDSs) are clonal disorders of the hematopoietic system, with morphologic dysplasia, ineffective hematopoiesis and peripheral blood cytopenias. MDS is currently classified according to the WHO (World Health Organization), which is based on the morphological, cytogenetic and hematological criteria and defines six subtypes. 1 In addition, the French American British classification, which comprises five subtypes, is also still in use. 2 The International Prognostic Scoring System (IPSS), a risk stratification system that takes into account clinical parameters as well as cytogenetic results, assigns four risk categories for death or transformation to acute myeloid leukemia (AML) (low, Int-1, Int-2 and high). Specific cytogenetic abnormalities were also included in the updated prognostic classification system. 3 Approximately 40-50% of MDS cases have a normal karyotype. MDS patients with a normal karyotype and low-risk clinical parameters are often assigned into the IPSS low and intermediate-1 risk groups.
In the absence of genetic or biological markers, prognostic stratification of these patients is difficult. To better prognosticate these patients, new parameters to identify patients at higher risk are urgently needed. With the more recently introduced modern technologies of whole-genome-wide surveys of genetic aberrations, it is hoped that more insights into the biology of disease progression might be obtained. Array comparative genomic hybridization (aCGH) studies with bacterial artificial chromosomes (BACs) or oligonucleotides using exclusively MDS samples are currently rare. The first BAC-based aCGH study of MDS and AML patients with trisomy 8 as sole cytogenetic aberration demonstrated that additional duplications and homozygous deletions can be detected, and that trisomy 8 is not always the primary genetic event. 4 Another BAC aCGH analysis of 38 MDS patients, 19 with and 19 without cytogenetic abnormalities, compared with a normal agematched control group revealed many cryptic aberrations, which were confirmed by other methods. 5 A BAC aCGH study using CD34
þ cells from 44 low-risk MDS patients (IPSS p1) included 25 cytogenetically normal cases. 6 This aCGH analysis uncovered hidden aberrations in the cytogenetically normal cases, but confirmed only 11 of 16 cytogenetically visible aberrations. These authors divided the patients into two groups based on the presence of a total of p3 Mb genomic aberrations (TGA) or 43 Mb TGA. It is not surprising that the group of 43 Mb TGA had a significant shorter overall survival, as most cases with large cytogenetically visible alterations fell into this group. A separate analysis of the 25 cytogenetically normal cases also showed a significant difference in overall survival in the group with 43 Mb TGA, although the numbers are still small. 6 Using oligonucleotide aCGH on MDS/AML with a 5q-syndrome or del(5) as the sole cytogenetic abnormality, we have described the presence of additional hidden aberrations in 2/12 patients. 7 With single-nucleotide polymorphism (SNP) arrays, copy number alterations as well as loss of heterozygosity through uniparental disomy (UPD) can be detected. Two reports described the use of SNP arrays to study low-risk MDS for hidden genomic imbalances. One SNP array study of 119 lowrisk MDS patients, 77 with a normal karyotype, 36 with visible cytogenetic alterations and 6 with unavailable cytogenetics, identified 125 UPDs with a median size of 3.78 Mb in 46% of the cases studied. 8 Another study showed that 82% of MDS patients harbor gains and losses detected by SNP arrays, whereas conventional cytogenetics detected alterations in 50%. 9 In addition, UPD was found in 33% of the patients. In both studies, first correlations of genomic imbalances including UPD with survival indicated that the presence of these may correlate with a shorter survival. 8, 9 This high rate of UPDs in MDS was recently challenged in a study that showed, when using buccal DNA samples from the same patients as controls, that only a small number of the potential loss of heterozygosity regions represent tumor-specific UPDs and gains and losses. 10 In that report only 4/33 cytogenetically normal cases had additional alterations.
To further explore the frequency of hidden genomic imbalances, specifically recurrent abnormalities, we performed a large retrospective study on 107 karyotypically normal MDS/ AML patients (WHO) using long oligonucleotides aCGH and non-amplified DNA. Recurrent and individual imbalances were detected, which correlated with an inferior survival.
Materials and methods

Patients, cytogenetic analysis and DNA isolation
In total, 107 cytogenetically normal MDS patients at the time of diagnosis and before therapy were included in this retrospective study. The patients had been entered into the Duesseldorf MDS registry and followed for survival. Median follow-up time was 28 months (1-150). Median survival time of the entire cohort was 32 months (1-150). The clinical details of the patients are shown in Table 1 . Approval for the study was obtained from the local ethics committee.
For conventional G-banding, bone marrow cells were cultivated for 24, 48 or 72 h in RPMI 1640 (Biochrom, Berlin, Germany) or Marrow Max Medium (Invitrogen, Gibco, Karlsruhe, Germany) with 10% fetal calf serum (Cytogen, Sinn, Germany). In total, 20-25 mitoses were analyzed according to the ISCN (International System for Human Cytogenetic Nomenclature), with a resolution of 100-300 bands. All 107 cases had a successful cytogenetic analysis. Material left over after cytogenetics was stored in methanol-acetic acid (3:1) at À20 1C. DNA was isolated from archived bone marrow samples with the QIAmp DNA Blood Midi Kit (Qiagen, Hilden, Germany) or with a phenol chloroform extraction. DNA concentration and purity were determined with the NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, NC, USA).
Oligonucleotide aCGH
For aCGH, 44k (n ¼ 37), 105k (n ¼ 21) or 244k (n ¼ 49) 60mer oligonucleotide microarrays were used (Human Genome CGH Microarray, Agilent Technologies, Palo Alto, CA, USA). CGH analyses were performed essentially as described in the protocol of the manufacturer (Protocol Version 5.0, June 2007; Agilent). Same-gender reference DNAs were purchased as pools (Promega, Mannheim, Germany). In total, 1.5 mg of cyanine 5-dUTPlabeled test DNA and cyanine 3-dUTP-labeled reference DNA were hybridized in the presence of Cot-1-DNA (Invitrogen) for 40 h (244, 105k) and 24 h (44k) at 65 1C. Arrays were washed (Wash Procedure B, Agilent) and slides were scanned with the Agilent array scanner G2505B.
Data analysis
Microarray images were scanned and Agilent's Feature Extraction Software Version 10.1 was used for quantification. Aberrant regions were determined by automatic breakpoint detection using the GLAD library 11 within the R Statistical Environment (http://www.r-project.org). All aberrations detected by two algorithms available in GLAD (smooth functions 'lawsglad' and 'haarseg'), covered by at least three oligonucleotides and with a minimum log2 ratio of ± 0.25, were mapped against the Database of Genomic Variants (http://projects.tcag.ca/variation) and UCSC (http://genome.ucsc.edu). In addition, for comparison we used data obtained from the analyses of mentally retarded patients in our diagnostic laboratory using the same arrays and the same evaluation parameters ('controls'). Imbalances were eliminated when they overlapped by 80% with those found in MDS patients. Regions overlapping o80% with known variants were selected for further visual inspection with Agilent's Genomic Workbench Software (Version 5.0.14) to define a set of aberrations for verification with fluorescence in situ hybridization (FISH), quantitative genomic real-time PCR (qPCR) or custom arrays. The complete data set is available at http://www.ncbi.nlm.nih.gov/geo/info/linking.html (accession no. GSE24602).
Validation of imbalances
Larger deletions and gains of several Mb were verified by FISH. BACs or fosmids were chosen from UCSC and purchased as described in Supplementary Table S1 . BAC DNA was isolated with the Qiagen Plasmid Midi Kit and indirectly labeled using either the BioNick DNA Labeling System (Invitrogen) and detected with streptavidin-cyanine 3 (Dianova, Hamburg, Germany) or the DIG-Nick Translation Mix and detected with anti-DIG-fluorescein (Roche, Mannheim, Germany). At least 200 interphases (and metaphases) were analyzed using a Zeiss Axioplan microscope (Gö ttingen, Germany) and ISIS software (MetaSystems, Altlussheim, Germany). Smaller deletions and gains were studied with qPCR using FastStart Universal SYBR Green Master (Rox) (Roche) and an ABI PRISM 7900 (Applied Biosystems, Carlsbad, CA, USA). Specific primer pairs were designed for each region. PCRs were run in triplicates and repeated once. For relative quantification, the delta delta Ct (threshold cycle) method was applied. P-values for fold changes were computed with two-sample t-tests, and corrected for multiple testing across qPCR experiments using the Bonferroni-Holm method. A combined male and female DNA pool (Promega), besides one or two normal DNA control samples, served as calibrator. As reference PRNP, a single copy gene was used.
TET2 exon amplification and mutation analysis
For mutation analysis of the coding sequence of TET2 (NM_001127208.1), all exons were amplified from sample P41 with specific primer pairs, mixed with normal DNA and analyzed by denaturing high-performance liquid chromatography (Supplementary Table S2A , B). Fragments with aberrant migration were subsequently sequenced.
Custom arrays
To determine the exact breakpoints of the deletions, we designed high-resolution custom arrays covering the affected genomic segments using the eArray internet platform (https://earray.chem.-agilent.com/earray/) of Agilent. Several formats were used, with an average genomic distance of 125 bp to 2 kb at the sites of the putative breakpoints. The arrays also covered the rest of the genome with a distance between 44 and 231 kb.
Identification of breakpoints
To determine the deletion end points, specific primer pairs were designed according to the results of the Agilent workbench data from the custom arrays. Long-range PCR conditions were used (Expand 20 kb Plus PCR System, Roche). DNA fragments were extracted from the gel (MEGA-spin Agarose Gel Extraction Kit, Intron Biotechnology, Gyeonggi-do, Korea), purified with ExoSAP-IT (Affymetrix, USB, Santa Clara, CA, USA) and sequenced.
Results
We investigated 107 MDS samples of various French American British subgroups at the time of diagnosis. Larger aberrations detected in X2 cases were studied first. Recurrent aberrations were identified in 4q (n ¼ 2), 5q (n ¼ 2), 7q (n ¼ 3) and 21q (n ¼ 2), and individual genomic imbalances occurred in an additional 34 cases. Interestingly, the recurrent deletions occurred on chromosomes 5 and 7 known to be frequently cytogenetically altered in MDS. The other two recurrent alterations affected two known tumor-associated genes, TET2 and RUNX1. All verified aberrations (n ¼ 40) and those fulfilling the above-described criteria but without verification (n ¼ 56) are listed in Table 2 .
Recurrent aberrations 4q24. Two cases had small deletions in 4q24 at the site of the TET2 gene. In P40, aCGH uncovered a homozygous deletion of 240 kb, removing the entire TET2 gene and flanking sequences (Figure 1a) . qPCR with specific primers in exon 2 of TET2 confirmed the homozygous deletion ( Figure 1b) . A custom array was hybridized to identify the breakpoints. Long-range PCR followed by sequencing showed that the deletion starts at 46.9 kb proximal and extends to 124.8 kb distal of TET2. This patient had an additional 6.6-Mb deletion in 2p23.3-p24.1 (Supplementary Figure S1A) , which was present in 96% of the cells as determined by FISH. In a follow-up sample 5 months later, the 2p deletion was reduced to 84%. The deletion in 2p harbors several interesting genes involved in epigenetic regulation (DNMT3A) and chromatin modification (ASXL2) (Supplementary Figure S1B) . The paralogous ASXL1 gene has been described as frequently mutated in MDS. 12 Interestingly, TET2 is probably involved in the regulation of cytosine methylation, pointing to two genes altered in this patient with a function in epigenetic regulation. Besides these two aberrations, no other genomic imbalances were noticed in this case. The patient had refractory anemia with excess blasts in transformation (RAEB-T) (AML according to the WHO classification), an IPSS score of high and died 10 months after diagnosis with AML.
A heterozygous deletion of B700 kb removing the PPA2, EEF1AL and TET2 genes was identified in case P41 and was verified by qPCR ( Figures 1a and b) . FISH determined that it was present in 67% of the cells. To test for mutations of the remaining alleles, all exons were analyzed and a missense mutation, p.C1135Y, in exon 3a of TET2 was detected. The same missense mutation was recently described as a somatic mutation in a patient with Myeloproliferative Neoplasm. 13 In this case several additional small aberrations were present, which were not studied further ( Table 2 ). The patient had lowrisk refractory anemia with multilineage dysplasia and ringed sideroblasts (IPSS 0), but survived only 3 months. The 5q31 deletion in patient P100 is to our knowledge the smallest 5q AML region deletion described so far. The deletion end points were identified by hybridization of a custom array. Sequences spanning the deleted region were amplified by longrange PCR and extensive sequence homology between the two breakpoints was observed; the break occurred on the proximal side in an AluJo and on the distal side in an AluSp element (manuscript in preparation). On the proximal side the MYOT gene is disrupted and 23 known genes map to this segment ( Figure 2d ). This patient (P100) with the small 5q31 and 7q22.1 deletion was diagnosed with refractory anemia with multilineage dysplasia, IPSS Int-1 and died after 12 months. In contrast, the patient (P52) with the larger 5q deletion and no other alteration was diagnosed as having refractory anemia with multilineage dysplasia and ringed sideroblasts, IPSS 1 and survived 43 years.
7q22. A 7q22.1 deletion with similar end points was found in three cases, P15, P70 and P100, with sizes of 2.1, 2.2 and Prognostic relevance of hidden imbalances in MDS A Thiel et al Prognostic relevance of hidden imbalances in MDS A Thiel et al positive log2 ratio, gain.
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Mb, respectively (Figure 3a
. FISH confirmed the deletion in 73, 85 and 87% of the cells (Figure 3b ). In addition, qPCR with intron 1/exon 2 primers of the CUX1 gene showed a relative copy number of 0.48 (P100) and 0.77 (P70) vs the pool calibrator (Figure 3c ). The deleted segment contains 50 named genes ( Figure 3a) . Segmental duplications and interspersed repeats flanking this region hampered the molecular identification of the breakpoints. Patient P70 had an additional interstitial 28-Mb deletion of 11q (Supplementary Figure S2) , which was seen by conventional cytogenetics in one metaphase and was therefore not included in the karyotype. Several interesting putative tumor suppressor (ts) genes map to this segment, for example ATM and MRE11, as well as genes involved in apoptosisFCASP1, 4, 12, BIRC2 and 3. This patient had RAEB-2 at diagnosis, progressed to RAEB-T after 5 months and died 7 months after diagnosis. The other patient, P15, with no additional imbalance, had RAEB-1, IPSS Int-1 and died after 15 months from infection.
21q22. Another recurrent deletion occurred at RUNX1/AML1
in 21q22.12 in two cases (Figure 4a ). Both were confirmed by FISH and were present in 94% (P39) and 89% (P24) of the cells. In a follow-up sample of case P24 after chemotherapy, the number of aberrant cells was below the cutoff for the probe. After hybridization of a custom array, the breakpoints could be identified and PCR products spanning the deletion were obtained (Figure 4b ) and sequenced. The actual sizes of the deletions were determined as 692 (P39) and 704 kb (P24). The larger deletion size identified after sequencing in case P39 was due to the lower resolution of the 44k array. In P39 the entire RUNX1 gene was deleted and in P24 only exon 1 and the 5 0 upstream region (Figure 4c ). Patient P24 with RAEB-T received induction chemotherapy and autologous stem cell transplantation and died 20 months later from septicemia. Patient P39 had no other genomic imbalances and had RAEB-2, an IPSS score of 3 and died 10 months after diagnosis of unknown cause.
A complex case with loss of 8ptel, gain of interrupted regions of 19p and gain of chromosome 21
In one case, P79, aCGH uncovered several imbalances, a complex rearrangement of chromosome 19 with a gain interrupted by two regions of a seemingly normal copy number, a gain of the entire chromosome 21 and loss of 8p22 to pter (Figure 5a ). FISH analysis with RP11-348B12 (19p13) revealed amplification in 17% of the cells with three to seven signals, suggesting an unstable karyotype. Both probes, 21q22 and 19p13, hybridized to four chromosomes, most likely representing an unbalanced translocation. The metaphases in Figure 5b show examples with various numbers of translocation chromosomes and three chromosomes with amplified signals. The 8p telomere deletion was verified by FISH, and simultaneous hybridization with probes from 19p13.3 and 8p23.1 showed that 17% of the cells had both aberrations. A schematic drawing of the identified alterations is shown in Figure 5b below the FISH results. In conclusion, all three aberrations were present in the same cell clone, demonstrating a complex cytogenetic result in a subset of cells. Limited material prevented further analyses. Although the cytogenetic analysis revealed a normal karyotype following the ISCN rules, there were several single aberrations. A follow-up sample after 4 months revealed cytogenetically visible aberrations: 46,XY [12] /45,XY,del(5)(q14q22),add(13) (p11),À14,À15,À17,À19,À21, þ 4mar [10] . In the follow-up sample, amplification of chromosome 21 and 19p13 was found in 41% of the interphase cells and 12% of the metaphases, demonstrating an increase in abnormal cells with cytogenetics and FISH. In addition, these results also showed that in this 
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Individual additional aberrations
Besides the eight patients with the recurrent alterations, 34 patients had additional individual copy number aberrations. In 22 cases a single aberration was observed; the other patients had between 2 and 14 aberrations. As no germ-line DNA was available from any of the patients, we could not determine whether these were constitutional. Most alterations were verified by FISH, qPCR or custom arrays (Table 2 ). Additional alterations identified by at least two algorithms but not verified by other methods are also listed in Table 2 . Some of these alterations were present in a high proportion of cells and therefore could be germ-line imbalances possibly contributing to MDS development. However, it should be pointed out that larger tumor-specific deletions were also present in a high proportion of cells when analyzed with FISH, for example the deletion 2p23.3-p24.1 in 96%. The same was observed by us previously for the del(5q), which was found in 35-91% of interphase cells. 7 It is remarkable that two patients had alterations affecting genes that are associated with elliptocytosis. Patient P20 had a deletion of 147 kb in 15q15 including the EPB42 (Supplementary Figure S3 ). Mutations in the EPB42 gene, coding for the erythrocyte protein band 4.2, are associated with recessive elliptocytosis and recessively transmitted hemolytic anemia. Patient P21 had a gain in 1q23.1 involving the SPTA1 (alpha spectrin, erythrocytic 1) gene and possibly disrupting it. Mutations in this gene result in a variety of hereditary red blood cell disorders, including elliptocytosis type 2, pyropoikilocytosis and spherocytic hemolytic anemia. The same patient had a gain in 1q42.3 disrupting the LYST gene; mutations in this gene are associated with Chediak-Higashi syndrome, a rare lysosomal storage disease. Features of this disease are large eosinophilic, peroxidase-positive inclusion bodies in myeloblasts and promyelocytes of the bone marrow, neutropenia, and abnormal susceptibility to infection and malignant lymphoma. Patients often die of hemorrhage, some secondary to thrombocytopenia. Both alterations affect only one copy of these genes and the associated diseases are recessive. Therefore, the observed alterations alone do not cause disease, but a combination of both (compound heterozygotes) may have contributed to MDS development. In addition, the same patient had two larger deletions in 14q and 10q in 40% of the cells as determined by FISH (Supplementary Figure S4A, B) , as well as 10 other smaller alterations (Table 2) . This patient had RAEB-2, an IPSS score of 1, received allogeneic stem cell transplantation and died 3 years after diagnosis of unknown cause.
Another patient (P30) had three alterations verified by custom arrays (Supplementary Figure S5) , two of which could contribute to MDS development: a deletion disrupting the RAB27 gene (autosomal recessive mutations cause Griscelli's syndrome and hemophagocytic syndrome) and a loss of the entire MCFD2 gene (autosomal recessive multiple coagulation factor deficiency, a rare bleeding disorder). In addition, a gain in the NOS1 gene, disrupting the genomic locus (blood pressure control), was identified. Two other imbalances in a lower percentage of cells were not verified yet. The patient had refractory anemia with multilineage dysplasia, IPSS Int-1 and died 6 months after diagnosis of gastrointestinal bleeding.
In patient P38 the large isoform of the MBP gene is disrupted by a deletion, which ends close to the 5 0 end of the shorter (hemopoietic, HMBP) isoform, possibly affecting its expression (Supplementary Figure S6) . The HMBP gene is expressed in CD34 þ bone marrow cells and all hematopoietic lineages. Patient P98 carried a 968-kb deletion in 3p26.2 in 100% of the cells as determined with FISH. The region corresponds in part to a known copy number variant, but two genes, ITPR1 and EGO, map outside of the variant region. The EGO gene codes for a non-coding RNA with increased expression following IL5 stimulation of CD34 þ cells. 14 Therefore, this gene might have a regulatory function in hematopoietic cell differentiation. A deletion of the WWOX gene occurred in P90, which affected two separate regions as identified by a custom array (Supplementary Figure S7) . WWOX maps to a fragile site (FRA16B) Figure 3 Identification of three similar 7q22 deletions in P15, P70 and P100. (a) Approximate breakpoints of the deletions in the three cases based on the GLAD algorithm (UCSC). Segmental duplications on either side are shown. (b) FISH analysis using a probe mapping to 7q22 in combination with a centromere 7 probe confirmed the deletion in case P15. In case P100, two BAC probes mapping within the deletion confirmed the deletion, as only one chromosome 7 is labeled. (c) qPCR analysis of two cases (P70 and P100) using primers from the CUX1 gene verified the deletion in both cases with a relative copy number of 0.77 in P70 and 0.48 in P100. The deletion was found in 84 and 87% of the cells, respectively, by FISH. Error bars are 95% confidence intervals, with an asterisk (*) indicating statistically significant fold changes (Pp0.05).
frequently altered in many different types of tumors. It encodes a substantiated ts gene. 15 Gains occurred in 21/42 cases; some patients had more than one and most were small. Patient P106 had a gain in 3q26.1 at the position of the MDS1/EVI1 gene, which affected only the shorter EVI1 gene (Figure 6a) . The gain was an amplification, present in 49% of the cells, as evidenced by the presence of EVI1 probe signals (green) on several different chromosomes (Figure 6b ). Limited material of poor quality prevented the identification of the sites of EVI1 insertion. A high expression of the EVI1 gene was found to predict poor survival in de novo AML patients. 16 The patient had RAEB-2, IPSS 2 and received an allogeneic stem cell transplantation and is still alive after 12 months.
Further gains containing several genes were identified: for example, in 7q21.2 (P11) containing the CYP51A gene, encoding a monooxygenase, which is a member of the cytochrome P450 proteins, catalyzing many reactions involved in drug metabolism and synthesis of cholesterol and steroids; in 21q22.3, a region containing among others two ribosomal genes, RRP1B and RRP1 (P34) ( Table 2 ); in 8q22.1 (P38) with a gain of the entire INTS8 gene, which is a subunit of the integrator complex with a role in processing of small nuclear RNAs and disruption of CCNE2 (Supplementary Figure S6) ; in 16q24 with a gain of several entire genes, for example, the ribosomal protein RPL13, CHMP1A, a chromatin-modifying protein, CDK10, a cyclin-dependent kinase with a function in the G2-M phase of the cell cycle and possibly disruption of the FANCA gene at the border of the gain (P50) (Supplementary Figure S8 ; Table 2 ). Another gain in case P72 included the entire LRRK2 gene; point mutations but not gains in this gene are found in patients with Parkinson's disease. Of note, it has been described that overexpression of wild-type human LRRK2 protects Caenorhabditis elegans after exposure to mitochondrial toxins, 17 and therefore this gain of the intact gene may have contributed to the development of MDS.
Correlation with clinical parameters
The median survival was 56 months in the patient group without alterations as compared with 20 months in patients with alterations (P ¼ 0.002). The Kaplan-Meier curve for all patients with and without aberrations is shown in Figure 7a and the subset of patients with low-risk MDS (IPSS low and intermediate-1) is shown in Figure 7b (57 vs 26 months, P ¼ 0.017). This further supports the notion that hidden alterations detected with aCGH may have a prognostic impact.
Discussion
In this aCGH study of the first large series of exclusively cytogenetically normal MDS samples, we show that MDS patients with a normal karyotype have a few recurrent copy number changes and several individual alterations. The four recurrent aberrations involve genes/chromosomal segments previously known to be affected in MDS. Two patients had deletions in 4q removing the entire TET2 gene. Although TET2 was identified as the most frequently mutated gene in MDS, [18] [19] [20] its role in disease remains controversial; two reports describe no impact of TET2 mutations on survival in MDS/MPD (myeloproliferative disease), 18, 21 another describes an association with decreased overall survival in AML 13 and, most recently, TET2 mutations were reported to be an independent favorable prognostic factor in MDS. 22 Two patients had submicroscopic deletions in 5q; one was only 1.35 Mb in 5q31.2, affecting the more proximal AML/MDS region. The deletion includes all candidate ts genes described so far in this region: CTNNA, 23 EGR1 24 and HSPA9, which shows increased expression during EPO-induced erythroid differentiation. 25, 26 In addition, other genes involved in cell cycle regulation, CDC25C and CDC23, and in chromatin modification, JMJD1B, a lysine-specific histone demethylase and previously described candidate ts gene from 5q 27 are localized in this segment. A recently described study of exon sequencing for all genes from this segment revealed no mutations in any of these genes, 28 further supporting the notion that the haploinsufficiency of one or more genes from this interval is the disease mechanism. It was described that the dual-specific phosphatase CDC25C is inhibited by lenalidomide and that expression of this gene was lower in AML and MDS with del(5q); 29 therefore, haplodeficiency of proteins might also have a role. This deletion does not include the typical 5q deletion in MDS mapping more distal in 5q31-32.
A basically identical deletion in 7q22.1 was found in three patients and overlaps with a commonly deleted segment in chronic myelogenous leukemia and maps outside the commonly deleted segment in MDS and AML. 30 A deletion spanning at least a segment between PLANH1/SERPINE and CUTL1/CUX1 was described in an apparently balanced translocation t(7;7)(p13;q22) 31 and maps to the deleted segment in the patients described here. Deletions with similar breakpoints were described in two patients with refractory anemia 6 and in two patients with chronic myelomonocytic leukemia. 32 Taken together, this del(7q22) with similar deletion end points seems to be a frequent recurrent hidden aberration. Although the deletion in 8ptel can be seen in the Agilent workbench program, the log ratio is very low. By chance a probe close to the homozygous deletion of a copy number variant (CNV) in 8p was used and the deletion was identified in 17% of the cells with FISH. This deletion was present in the same clones that also carried the other alterations. Therefore, in this case a complex cytogenetic result was present in B17% of the cells.
Several interesting genes map to this genomic segment, including EPO, TRF2, EPHB4 and CLDN15. The TFR2 gene encoding a transferrin receptor is highly expressed in CD34 þ hematopoietic cells and has an important function in mitochondrial iron metabolism. Mutations in this gene cause one type of hemochromatosis, associated with iron overload. 33 The homeobox gene CUX1 functions as a transcriptional activator or repressor. EPHB4 is expressed in hematopoietic progenitor cells and is downregulated during differentiation to mature erythroid cells upon removal of its ligand. 34 Active EphB4 enforces preferentially megakaryocytic and erythroid differentiation. It was described that the ephrinB2/EphB4 axis is dysregulated in multiple myeloma. 35 In addition, several genes in this region are involved in regulation of RAS signaling, for example, RABL5, RASA4, SH2B2 and GNB2.
Cytogenetically visible monosomy 7 or deletions (7q) are currently poor IPSS risk factors. At present, it is unknown whether submicroscopic deletions of 7q22 have the same clinical impact.
Two patients had deletions disrupting the RUNX1 gene. The critical regulatory role of RUNX1 for development of all hematopoietic cell types is well established. The functional consequence of mutations in RUNX1 can be haploinsufficiency or a dominant-negative effect. This gene is also the most frequent target for chromosomal translocations in leukemia and the fusion protein inhibits the function of the native allele. 36 So far only a few RUNX1 deletions have been described in MDS (for example, Heinrichs et al. 10 and Gondek et al. 32 ). Inactivation of the normal RUNX1 function is not sufficient to cause leukemia and other cooperating alterations were postulated.
Most alterations presented in this work were verified by other methods and several deletion breakpoints were identified by sequencing (manuscript in preparation). In our study, 39% of the samples had hidden aberrations, whereas higher numbers of aberrations were reported using SNP arrays, which can also detect copy number neutral allelic imbalances. However, recently it was shown that using normal genomic DNA from the same patients for comparison is mandatory to avoid false discoveries in SNP array studies. 37 Furthermore, in most SNP studies the alterations were not verified with other methods as we have done for many alterations. Similar to our results, Praulich et al., 38 who studied childhood MDS with BAC and oligonucleotide arrays, found a low frequency of hidden aberrations, which were verified with other methods. Future SNP array analyses using paired normal and tumor samples and aCGH studies using karyotypically normal samples will have to unravel whether UPD is indeed a more frequent aberration in MDS.
In our large series of karyotypically normal patients, we found a significantly shorter time to death from diagnosis for patients with additional aberrations, which is also seen when only those patients with a low-risk MDS are analyzed. In addition, the presence of genes involved in epigenetic and chromatin modification in several of the altered regions further emphasizes the important role of epigenetic modifications for MDS Figure 6 Amplification of EVI1 in P106. (a) A gain in 3q26 was identified, including the entire EVI1 gene and disrupting the longer MDS1/EVI1 gene, as can be seen in gene view (Agilent setting: ADM-2, threshold 6). The position of the FISH probes from the EVI t(3;3) inv(3)(3q26) break apart probe used for verification of the amplification is marked as 3q26 distal (red) and 3q26 proximal (green). The EVI1 gene itself is not localized on these probes, but flanked by the proximal green and distal red probes. (b) FISH analysis using this probe mix revealed an amplification of the proximal green signal and, as deduced from the array result the amplification includes the EVI1 gene, whereas the MDS1 gene maps outside of the amplification. The interphase (top) shows six green signals and the metaphase (bottom) demonstrates that the amplified DNA containing the EVI1 gene is present on various chromosomes. development. It is expected that future functional studies of the genes in the aberrant regions and pathway analyses may help to uncover common genetic events leading to MDS development and, in the future, may reveal new targets for therapy.
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The authors declare no conflict of interest Time from diagnosis to death for patients with low-risk MDS (IPSS 0 and 1) with and without aberrations. When only the low-risk patients were analyzed, a significant shorter survival was also observed for patients with aberrations (P ¼ 0.017).
